首页>投融资
DiogenX
A轮
DiogenX is a preclinical stage biotech company focused on the development of pancreatic beta cell modulators for the treatment of type 1 diabetes.In June 2020, the company closed a round of EUR € 4.5 million (US $ 5.07295 million)
基本信息
-
公司全称DiogenX
-
类型
-
产业领域药品研发/制造
-
公司人数15人以下
-
地址180 avenue du Prado MARSEILLE PACA 13008; FR;
-
联系电话
-
邮箱saffiyah@ala.associates
-
成立时间2019-01-01
投融资
-
2023-05-10A轮2750万欧元Omnes CapitalAdBio partnersEli LillyJDRF T1D FundRoche Venture FundBoehringer Ingelheim Venture Fund
-
2023-05-10A轮2750万欧元Omnes CapitalJDRF T1D FundRoche Venture Fund勃林格殷格翰风险基金AdBio partnersEli Lilly
-
2020-06-16种子轮450万欧元Advent France BiotechnologyJDRF T1D FundBoehringer Ingelheim Venture Fund
-
2020-06-16种子轮450万欧元JDRF T1D Fund勃林格殷格翰风险基金Advent France Biotechnology
- 加载更多
相关投融资企业
PreA轮
Epitopea Ltd develops cancer immunotherapies intended to offer therapeutics targeting a novel class of tumour-specific antigen. The company's technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, curing cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication.In May 2022, Novateur Ventures had participated in the $13.6M (£10.3M) seed investment raised by Epitopea Ltd.In April 2022, Epitopea had announced a $13.6M seed investment from Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital and Fonds de solidarité FTQ
C轮
Alpha-9 Oncology 是一家处于临床阶段的放射性药物公司，致力于开发差异化和高度靶向性的放射性药物，有望显著改善癌症患者的治疗。Alpha-9 运用专有技术和深厚的基础专业知识，走在定制放射性药物工程的前沿，这些药物经过优化，可选择性地向肿瘤部位输送射线，同时最大限度地减少脱靶效应。Alpha-9 正在推进一个强大的新型放射性药物管线，该管线采用系统化的分子设计方法，具有向多个有效肿瘤靶点扩展的广泛潜力。
A轮
March Biosciences是一家临床阶段生物技术公司。该公司致力于治疗对现有免疫疗法无反应的挑战性癌症。其主要资产MB-105是一种以CD5为靶点的嵌合抗原受体T细胞（“CAR-T”）疗法，CD5是一个在正常和恶性T细胞（包括T细胞相关的白血病和淋巴瘤）中广泛表达的蛋白质。这限制了其作为癌症治疗靶点的用途，因为正常免疫系统功能所需的健康T细胞将与恶性T细胞一起被破坏。MB-105经过特别设计，既能保留健康的T细胞，又能保持对CD5阳性肿瘤细胞的杀伤力。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息